Updates are available Correction dated 2022-12-19

Article History

Received: 26 July 2022

Accepted: 20 October 2022

First Online: 18 November 2022

Change Date: 19 December 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s10194-022-01530-9

Declarations

:

: The SQUARE study was approved by the competent lead ethics committee (Ethikkommission Nordwest- und Zentralschweiz EKNZ) in February 2019 and can therefore be found under BASEC ID 2018–02375 in the Register of All Projects in Switzerland (RAPS).

: All authors read and approved the final manuscript.

: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: ARG reports honorarium and/or consulting fees from Allergan, Almirall, Amgen, Curatis, Eli Lilly, Grünenthal, Lundbeck, Novartis and TEVA Pharmaceuticals. RA report honoraria for speaker, advisory board and/or investigator activities from Allergan, Almogran, Drossa Pharma, Eli Lilly, Lundbeck, Medical Tribune (Biomed, Schwabe), Merz, Novartis and TEVA. CPK has received honoraria for lectures as well as research support from Almirall, Biogen, Celgene, Eli Lilly, Janssen, Merck, Novartis, Roche, Sanofi Genzyme, Swiss MS Society (SMSG) and Teva. GL reports honorarium and/or consulting fees from Almirall, Eli Lilly, Grünenthal, Novartis and Pfizer. NM reports honorarium for his participation to an advisory board from Novartis. GSM reports honoraria for advisor and speaker activities from Novartis. HP received honoraria from Eli Lilly, speaker fees from Novartis and TEVA Pharmaceuticals as well as fundings from the Werner Dessauer Stiftung. PR's institution has received fees for his participation to advisory boards or speaker fees from Eli-Lilly, Lundbeck Novartis, and Teva pharmaceuticals. CJS received consulting, advisory boards and speaker fees as well as travel support from Allergan, Almirall, Amgen, Eli Lilly, Grünenthal, Lundbeck, MindMed, Novartis, TEVA Pharmaceuticals; part-time-employee at Zynnon, and has received funding from Baasch-Medicus Foundation Deutsche Migräne- und Kopfschmerzgesellschaft (ExternalRef removed) and Swiss Heart Foundation outside the submitted work. JAP declared no conflict of interests. DV received financial support for consultancies and research from Eli Lilly, Novartis and Teva Pharma. CZ has received honoraria for advisory boards from the Swiss MS Society. Ente Ospedaliero Cantonale (employer) received compensation for C.Z.’s speaking activities, consulting fees, or research grants from Almirall, Biogen Idec, Bristol Meyer Squibb, Lundbeck, Merck, Novartis, Sanofi, Teva Pharma, Roche. CZ is recipient of a grant for senior reseachers provided by AFRI (Area Formazione accademica, Ricerca ed Innovazione). ES, IM, and MEA are employees of Novartis Pharma Schweiz AG.